Neogenomics Inc [NEO] stock prices are down -1.91% to $7.69 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NEO shares have gain 16.87% over the last week, with a monthly amount drifted -12.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neogenomics Inc [NASDAQ: NEO] stock has seen the most recent analyst activity on April 30, 2025, when Leerink Partners downgraded its rating to a Market Perform but kept the price target unchanged to $9 for it. Previously, The Benchmark Company downgraded its rating to Hold on January 13, 2025. On December 10, 2024, Jefferies initiated with a Buy rating and assigned a price target of $22 on the stock. BTIG Research reiterated its recommendation of a Buy and reduced its price target to $21 on December 29, 2023. Stephens upgraded its rating to Overweight for this stock on August 21, 2023, but kept the price target unchanged to $18. In a note dated May 16, 2023, Raymond James downgraded an Mkt Perform rating on this stock.
The stock price of Neogenomics Inc [NEO] has been fluctuating between $6.08 and $19.11 over the past year. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Neogenomics Inc [NASDAQ: NEO] shares were valued at $7.69 at the most recent close of the market. An investor can expect a potential return of 95.06% based on the average NEO price forecast.
Analyzing the NEO fundamentals
The Neogenomics Inc [NASDAQ:NEO] reported sales of 672.36M for trailing twelve months, representing a surge of 7.55%. Gross Profit Margin for this corporation currently stands at 0.44% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.12%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.09 and Total Capital is -0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.50 points at the first support level, and at 7.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.06, and for the 2nd resistance point, it is at 8.43.
Ratios To Look Out For
It’s worth pointing out that Neogenomics Inc [NASDAQ:NEO]’s Current Ratio is 2.05. In addition, the Quick Ratio stands at 1.94 and the Cash Ratio stands at 1.24. Considering the valuation of this stock, the price to sales ratio is 1.47, the price to book ratio is 1.11.
Transactions by insiders
Recent insider trading involved Sherman Jeffrey Scott, Chief Financial Officer, that happened on May 02 ’25 when 20000.0 shares were purchased. General Counsel, Olivo Alicia C completed a deal on Nov 15 ’24 to sell 5175.0 shares. Meanwhile, Officer ALICIA OLIVO bought 5175.0 shares on Nov 15 ’24.
